前列腺素F2α與特發性肺間質纖維化相關性的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

雷文濤 ¹ ,  岳紅梅 ^1,2 , 黃浩 ¹ , 王俊敏 ¹ , 仵晨雨 ¹

1. ;
2. ;

Corresponding?author：

岳紅梅, Email: yuehongmei18@sina.com

Keywords：

DOI：

10.7507/1671-6205.202012090

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 雷文濤, 岳紅梅, 黃浩, 王俊敏, 仵晨雨. 前列腺素F2α與特發性肺間質纖維化相關性的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(12): 905-908. doi: 10.7507/1671-6205.202012090 Copy

1.	Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med, 2018, 198(5): e44-e68.
2.	Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J, 2015, 46(3): 795-806.
3.	黃慧, 李珊, 張倩, 等. 特發性肺纖維化診斷臨床指南(摘譯). 中華結核和呼吸雜志, 2018, 41(12): 915-920.
4.	Sugimoto Y, Inazumi T, Tsuchiya S, et al. Roles of prostaglandin receptors in female reproduction. J Biochem, 2015, 157(2): 73-80.
5.	Yamagishi-Kimura R, Honjo M, Aihara M, et al. Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension. Sci Rep, 2018, 8(1): 11098.
6.	Maehara T, Higashitarumi F, Kondo R et al. Prostaglandin F_2α receptor antagonist attenuates LPS-induced systemic inflammatory response in mice. FASEB J, 2020, 34(11): 15197-15207.
7.	Aihara K, Handa T, Oga T, et al. Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. PLoS One, 2013, 8(6): e66017.
8.	Oga T, Matsuoka T, Yao C, et al. Prostaglandin F_2α receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-β. Nat Med, 2009, 15(12): 1426-1430.
9.	Peebles RS Jr. Prostaglandins in asthma and allergic diseases. Pharmacol Ther, 2019, 193: 1-19.
10.	Claar D, Hartert TV, Peebles RS Jr, et al. The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med, 2015, 9(1): 55-72.
11.	Jaén RI, Prieto P, Casado M, et al. Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer: an update. World J Gastroenterol, 2018, 24(48): 5454-5461.
12.	Basu S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F_2α from physiology to new principles in inflammation. Med Res Rev, 2007, 27(4): 435-468.
13.	Kaczynski P, Kowalewski MP, Waclawik A, et al. Prostaglandin F2α promotes angiogenesis and embryo-maternal interactions during implantation. Reproduction, 2016, 151(5): 539-552.
14.	Sedlak L, Zych M, Wojnar W, et al. Effect of topical prostaglandin F2α analogs on selected oxidative stress parameters in the tear film. Medicina (Kaunas), 2019, 55(7): 366.
15.	Kashiwagi H, Yuhki KI, Imamichi Y, et al. Prostaglandin F2α facilitates platelet activation by acting on prostaglandin E2 receptor subtype EP3 and thromboxane A2 receptor TP in mice. Thromb Haemost, 2019, 119(8): 1311-1320.
16.	Ohyama K, Sugiura M. [Evaluation of the association between topical prostaglandin F2α analogs and asthma using the JADER database: comparison with β-blockers]. Yakugaku Zasshi, 2018, 138(4): 559-564.
17.	Liu B, Li J, Yan H, et al. TP and/or EP3 receptors mediate the vasoconstrictor and pressor responses of prostaglandin F_2α in mice and/or humans. FASEB J, 2019, 33(2): 2451-2459.
18.	Wanderer S, Mrosek J, Gessler F, et al. Levosimendan reduces prostaglandin F2a-dependent vasoconstriction in physiological vessels and after experimentally induced subarachnoid hemorrhage. Curr Neurovasc Res, 2018, 15(1): 72-80.
19.	Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol, 2015, 15(8): 511-523. Erratum in: Nat Rev Immunol, 2015, 15(11): 724.
20.	Basu S. Bioactive eicosanoids: role of prostaglandin F_2α and F?-isoprostanes in inflammation and oxidative stress related pathology. Mol Cells, 2010, 30(5): 383-391.
21.	Sharif NA, Klimko PG. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol, 2019, 176(8): 1059-1078.
22.	趙存剛, 黃文海, 王尊元, 等. 轉化生長因子-β在特發性肺纖維化中的研究新進展. 中國藥學雜志, 2016, 51(5): 341-345.
23.	Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax, 1993, 48(10): 959-966.
24.	Wang Q, Wang Y, Hyde DM, et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters. Thorax, 1999, 54(9): 805-812.
25.	Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest, 1999, 104(1): 5-11.
26.	Kapoun AM, Gaspar NJ, Wang Y, et al. Transforming growth factor-β receptor type 1 (TGFβRI) kinase activity but not p38 activation is required for TGFβRI-induced myofibroblast differentiation and profibrotic gene expression. Mol Pharmacol, 2006, 70(2): 518-531.
27.	Nagase T, Uozumi N, Ishii S, et al. A pivotal role of cytosolic phospholipase A₂ in bleomycin-induced pulmonary fibrosis. Nat Med, 2002, 8(5): 480-484.
28.	Taylor L, Polgar P, McAteer JA, et al. Prostaglandin production by type Ⅱ alveolar epithelial cells. Biochim Biophys Acta, 1979, 572(3): 502-509.
29.	Lappi-Blanco E, Kaarteenaho-Wiik R, Maasilta PK, et al. COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am J Clin Pathol, 2006, 126(5): 717-724.
30.	Hsueh W. Prostaglandin biosynthesis in pulmonary macrophages. Am J Pathol, 1979, 97(1): 137-148.
31.	Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary (99 m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax, 2001, 56(12): 916-923.
32.	Beck H, Thaler T, Meibom D, et al. Potent and selective human prostaglandin F (FP) receptor antagonist (BAY-6672) for the treatment of idiopathic pulmonary fibrosis (IPF). J Med Chem, 2020, 63(20): 11639-11662.
33.	Suga M, Iyonaga K, Ichiyasu H, et al. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J, 1999, 14(2): 376-382.
34.	Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med, 2005, 2(9): e251.
35.	Taneja A, Desrivot J, Diderichsen PM, et al. Population pharmacokinetic and pharmacodynamic analysis of GLPG1690, an autotaxin inhibitor, in healthy volunteers and patients with idiopathic pulmonary fibrosis. Clin Pharmacokinet, 2019, 58(9): 1175-1191.
36.	Sgalla G, Flore M, Siciliano M, et al. Antibody-based therapies for idiopathic pulmonary fibrosis. Expert Opin Biol Ther, 2020, 20(7): 779-786.
37.	Raghu G, van den Blink B, Hamblin MJ, et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med, 2019, 7(8): 657-664.

1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med, 2018, 198(5): e44-e68.
2. Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J, 2015, 46(3): 795-806.
3. 黃慧, 李珊, 張倩, 等. 特發性肺纖維化診斷臨床指南(摘譯). 中華結核和呼吸雜志, 2018, 41(12): 915-920.
4. Sugimoto Y, Inazumi T, Tsuchiya S, et al. Roles of prostaglandin receptors in female reproduction. J Biochem, 2015, 157(2): 73-80.
5. Yamagishi-Kimura R, Honjo M, Aihara M, et al. Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension. Sci Rep, 2018, 8(1): 11098.
6. Maehara T, Higashitarumi F, Kondo R et al. Prostaglandin F_2α receptor antagonist attenuates LPS-induced systemic inflammatory response in mice. FASEB J, 2020, 34(11): 15197-15207.
7. Aihara K, Handa T, Oga T, et al. Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. PLoS One, 2013, 8(6): e66017.
8. Oga T, Matsuoka T, Yao C, et al. Prostaglandin F_2α receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-β. Nat Med, 2009, 15(12): 1426-1430.
9. Peebles RS Jr. Prostaglandins in asthma and allergic diseases. Pharmacol Ther, 2019, 193: 1-19.
10. Claar D, Hartert TV, Peebles RS Jr, et al. The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med, 2015, 9(1): 55-72.
11. Jaén RI, Prieto P, Casado M, et al. Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer: an update. World J Gastroenterol, 2018, 24(48): 5454-5461.
12. Basu S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F_2α from physiology to new principles in inflammation. Med Res Rev, 2007, 27(4): 435-468.
13. Kaczynski P, Kowalewski MP, Waclawik A, et al. Prostaglandin F2α promotes angiogenesis and embryo-maternal interactions during implantation. Reproduction, 2016, 151(5): 539-552.
14. Sedlak L, Zych M, Wojnar W, et al. Effect of topical prostaglandin F2α analogs on selected oxidative stress parameters in the tear film. Medicina (Kaunas), 2019, 55(7): 366.
15. Kashiwagi H, Yuhki KI, Imamichi Y, et al. Prostaglandin F2α facilitates platelet activation by acting on prostaglandin E2 receptor subtype EP3 and thromboxane A2 receptor TP in mice. Thromb Haemost, 2019, 119(8): 1311-1320.
16. Ohyama K, Sugiura M. [Evaluation of the association between topical prostaglandin F2α analogs and asthma using the JADER database: comparison with β-blockers]. Yakugaku Zasshi, 2018, 138(4): 559-564.
17. Liu B, Li J, Yan H, et al. TP and/or EP3 receptors mediate the vasoconstrictor and pressor responses of prostaglandin F_2α in mice and/or humans. FASEB J, 2019, 33(2): 2451-2459.
18. Wanderer S, Mrosek J, Gessler F, et al. Levosimendan reduces prostaglandin F2a-dependent vasoconstriction in physiological vessels and after experimentally induced subarachnoid hemorrhage. Curr Neurovasc Res, 2018, 15(1): 72-80.
19. Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol, 2015, 15(8): 511-523. Erratum in: Nat Rev Immunol, 2015, 15(11): 724.
20. Basu S. Bioactive eicosanoids: role of prostaglandin F_2α and F?-isoprostanes in inflammation and oxidative stress related pathology. Mol Cells, 2010, 30(5): 383-391.
21. Sharif NA, Klimko PG. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol, 2019, 176(8): 1059-1078.
22. 趙存剛, 黃文海, 王尊元, 等. 轉化生長因子-β在特發性肺纖維化中的研究新進展. 中國藥學雜志, 2016, 51(5): 341-345.
23. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax, 1993, 48(10): 959-966.
24. Wang Q, Wang Y, Hyde DM, et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters. Thorax, 1999, 54(9): 805-812.
25. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest, 1999, 104(1): 5-11.
26. Kapoun AM, Gaspar NJ, Wang Y, et al. Transforming growth factor-β receptor type 1 (TGFβRI) kinase activity but not p38 activation is required for TGFβRI-induced myofibroblast differentiation and profibrotic gene expression. Mol Pharmacol, 2006, 70(2): 518-531.
27. Nagase T, Uozumi N, Ishii S, et al. A pivotal role of cytosolic phospholipase A₂ in bleomycin-induced pulmonary fibrosis. Nat Med, 2002, 8(5): 480-484.
28. Taylor L, Polgar P, McAteer JA, et al. Prostaglandin production by type Ⅱ alveolar epithelial cells. Biochim Biophys Acta, 1979, 572(3): 502-509.
29. Lappi-Blanco E, Kaarteenaho-Wiik R, Maasilta PK, et al. COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am J Clin Pathol, 2006, 126(5): 717-724.
30. Hsueh W. Prostaglandin biosynthesis in pulmonary macrophages. Am J Pathol, 1979, 97(1): 137-148.
31. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary (99 m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax, 2001, 56(12): 916-923.
32. Beck H, Thaler T, Meibom D, et al. Potent and selective human prostaglandin F (FP) receptor antagonist (BAY-6672) for the treatment of idiopathic pulmonary fibrosis (IPF). J Med Chem, 2020, 63(20): 11639-11662.
33. Suga M, Iyonaga K, Ichiyasu H, et al. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J, 1999, 14(2): 376-382.
34. Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med, 2005, 2(9): e251.
35. Taneja A, Desrivot J, Diderichsen PM, et al. Population pharmacokinetic and pharmacodynamic analysis of GLPG1690, an autotaxin inhibitor, in healthy volunteers and patients with idiopathic pulmonary fibrosis. Clin Pharmacokinet, 2019, 58(9): 1175-1191.
36. Sgalla G, Flore M, Siciliano M, et al. Antibody-based therapies for idiopathic pulmonary fibrosis. Expert Opin Biol Ther, 2020, 20(7): 779-786.
37. Raghu G, van den Blink B, Hamblin MJ, et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med, 2019, 7(8): 657-664.

Previous Article
原發性干燥綜合征合并間質性肺疾病臨床評估與治療進展

Chinese Journal of Respiratory and Critical Care Medicine

前列腺素F2α與特發性肺間質纖維化相關性的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content